LC‐MS/MS methods for the determination of edaravone and/or taurine in rat plasma and its application to a pharmacokinetic study |
| |
| Authors: | Dao‐quan Tang Ting‐ting Bian Xiao‐xiao Zheng Ying Li Xiao‐wen Wu Yin‐jie Li Qian Du Shui‐shi Jiang |
| |
| Affiliation: | 1. Department of Pharmaceutical Analysis, Xuzhou Medical College, Xuzhou, China;2. Key Laboratory of New Drug and Clinical Application, Xuzhou Medical College, Xuzhou, China;3. Nanjing Yoko Pharmaceutical Co. Ltd, Nanjing, China |
| |
| Abstract: | Three liquid chromatography–tandem mass spectrometry (LC‐MS/MS) methods were respectively developed and validated for the simultaneous or independent determination of taurine and edaravone in rat plasma using 3‐methyl‐1‐p‐tolyl‐5‐pyrazolone and sulfanilic acid as the internal standards (IS). Chromatographic separations were achieved on an Agilent Zorbax SB‐Aq (100 × 2.1 mm, 3.5 µm) column. Gradient 0.03% formic acid–methanol, isocratic 0.1% formic acid–methanol (90:10) and 0.02% formic acid–methanol (40:60) were respectively selected as the mobile phase for the simultaneous determination of two analytes, taurine or edaravone alone. The MS acquisition was performed in multiple reaction monitoring mode with a positive and negative electrospray ionization source. The mass transitions monitored were m/z M + H]+ 175.1 → 133.0 and M + H]+ 189.2 → 147.0 for edaravone and its IS, m/z M ? H]? 124.1 → 80.0 and M ? H]? 172.0 → 80.0 for taurine and its IS, respectively. The validated methods were successfully applied to study the pharmacokinetic interaction of taurine and edaravone in rats after independent intravenous administration and co‐administration with a single dose. Our collective results showed that there were no significant alterations on the main pharmacokinetic parameters (area under concentration–time curve, mean residence time, half‐life and clearance) of taurine and edaravone, implying that the proposed combination therapy was pharmacologically feasible. Copyright © 2014 John Wiley & Sons, Ltd. |
| |
| Keywords: | taurine edaravone intravenous administration pharmacokinetic LC‐MS/MS |
|
|
